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Biochemical markers predictive for bone marrow 
involvement in systemic mastocytosis
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Brief Report
ABSTRACT
Systemic mastocytosis is characterized by bone marrow involvement, which requires a bone marrow biopsy for diagnostic work-up. We
questioned whether bone marrow involvement could be predicted using biochemical markers. We selected patients with various symp-
toms suggestive of indolent systemic mastocytosis, of whom 63 ultimately had bone marrow involvement. Patients suspected of aggres-
sive mastocytosis, or mastocytosis associated with other hematologic diseases were excluded. Evaluation of 115 patients and 15
patient controls demonstrated a test accuracy for serum tryptase, urinary N– methylhistamine and N– methylimidazole acetic acid of
96%, 88% and 95% respectively. These markers provide an excellent pre-test probability of indolent systemic mastocytosis.
Key words: mastocytosis, bone marrow involvement, biochemical markers, tryptase, N–τ methylhistamine, N–τ methylimidazole acetic
acid.
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Introduction
Mastocytosis denotes a heterogeneous group of disorders
characterized by abnormal growth and accumulation of mast
cells in one or more organ systems. In systemic mastocytosis
the bone marrow is always involved.1 A bone marrow biop-
sy with appropriate immunohistochemical studies is consid-
ered the gold standard for diagnosis. Ancillary tests such as
mast cell immunophenotyping, cytogenetic/molecular stud-
ies, and serum tryptase levels assist in confirming the diagno-
sis.2 While patients with aggressive systemic mastocytosis
and mast cell leukemia are usually severely symptomatic,
adult patients with indolent mastocytosis frequently present
only with skin lesions and/or mediator-related symptoms.3
As these patients may be reluctant to undergo a bone mar-
row biopsy, it might be helpful if biochemical parameters
could select, with a high level of certainty, patients with and
without bone marrow involvement. Analysis of biochemical
mediators released by mast cells may be useful for screening
and diagnostic evaluation. 
We investigated the predictive value and accuracy of serum
tryptase and urinary N– methylhistamine (MH) and N–
methylimidazole acetic acid (MIMA) to predict bone marrow
involvement in indolent systemic mastocytosis. We retro-
spectively analyzed blood, urine, and bone marrow data of a
large cohort of adult patients who had been referred to our
department with the probable diagnosis of indolent systemic
mastocytosis.
Design and Methods
In 115 patients, a diagnosis of indolent systemic mastocy-
tosis was considered because of: biopsy-proven cutaneous
mastocytosis (all examinated by an experienced dermatolo-
gist: adult-onset n=33; pediatric-onset n=3), unexplained ana-
phylactic reaction (n=6), hymenoptera anaphylaxis (n=22) or
anaphylaxis in response to intravenous contrast material
(n=1; the diagnosis of anaphylaxis was based on criteria as
described in a recent paper by Sampson et al.4), mediator-
related symptoms such as flushing, pruritus, abdominal pain,
nausea, vomiting, diarrhea (n=16), unexplained severe osteo-
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porosis (n=7) or combinations thereof (n=27). Patients
with clinical B and C findings suggestive of aggressive
mastocytosis were excluded from the study along with
patients with a probable diagnosis of systemic masto-
cytosis with an associated hematologic non-mast cell
lineage disease.2 Fifteen patients who underwent a
bone marrow biopsy for reasons not related to mast
cell pathology served as controls. In these patients,
bone marrow biopsies were performed for: analysis of
competence as a bone marrow donor (n=1), cytopenia
of any type (n=4), staging of non-hematologic malig-
nancy (n=5), and exclusion of myeloproliferative disor-
der (n=3) or systemic amyloidosis (n=2). A bone mar-
row biopsy was performed and tryptase, MH and
MIMA were determined for all patients and patient
controls. The median interval (range) between bone
marrow and blood/urine analysis was 0 (0-365) days.
This time interval was acceptable if clinical symptoms
remained unchanged because, in fact, biochemical
parameters of patients with proven indolent mastocy-
tosis are usually stable for several years.5
Tryptase levels were determined using the B12
assay.6 Levels of MH were determined by an isotope-
dilution mass fragmentographic method.7 MIMA was
determined as previously described8 with some modifi-
cations using isotope dilution mass fragmentography.
Bone marrow biopsies were taken from the iliac crest
by an experienced hematologist using the Jamshidi
technique. The bone marrow core required a minimal
length of 20 mm to be considered representative. All
formalin-fixed paraffin-embedded (n=106) samples
were stained using the Avidin-Biotin system for
tryptase (clone AA1 from Dakocytomation, Glostrup,
Denmark) and CD117 (Dakocytomation) expression.
Tissue sections were stained by toluidin-blue for biop-
sies embedded in plastic (n=24). 
For bone marrow mast cell immunophenotyping,
300,000 events were analyzed using four-color staining,
including CD45, CD117, CD2 and CD25 as previously
described.9 KIT mutation analysis was performed as
previously described.10, 11
All bone marrow biopsies were revised blinded, and
scored for the presence of major and minor criteria
according to the WHO classification12 by an experi-
enced hematopathologist (PMK). Obviously, serum
tryptase as a minor criterion was omitted for this spe-
cific study. 
For statistical analysis, patients were grouped into
positive or negative for systemic mastocytosis by out-
come of bone marrow revision, the additional minor
criteria CD2 and/or CD25 expression by KIT positive
mast cells, and the D816V KIT mutation.12 Receiver
operator characteristic (ROC) curves were constructed
with Analyse-It (Analyse-It Software, Leeds, United
Kingdom) to examine the diagnostic value of each ana-
lyte. Furthermore, we analyzed whether combinations
of the three biochemical markers could increase the
predictive value for bone marrow involvement com-
pared with each marker alone.
Results and Discussion
Patient characteristics of both groups were compara-
ble (see Table 1). Both groups consisted of comparable
subjects. Results from bone marrow histology and
additional WHO minor criteria are shown in Figure 1.
Fifty-nine patients showed one major and one or more
minor criteria for the diagnosis of systemic mastocyto-
sis. In 51 patients, a diagnosis of systemic mastocytosis
could not be made. In this retrospective study, addi-
tional data on flow cytometry or KIT mutation analysis
were sometimes lacking (Table I). However, we decid-
ed not to repeat these tests, either because there were
already sufficient major and minor criteria for the diag-
nosis of systemic mastocytosis or because all other cri-
teria were negative, indicating that no diagnosis of sys-
temic mastocytosis could be made. Given that our
study aim was to evaluate whether serum tryptase and
the urinary metabolites MH and MIMA could predict
systemic mastocytosis, all WHO major and minor cri-
teria were used except serum tryptase. Consequently, 2
patients, whose diagnosis of systemic mastocytosis
was based on this criterion (tryptase 23.9 and 28.9
mg/L, respectively), were excluded from further study
(Figure 1).
ROC analyses were performed to study the sensitiv-
Table 1. Clinical and laboratory characteristics of subjects.
Patients (n=115) Controls (n=15)
Patient characteristics
Age (years) [median, range] 49 (16-82) 54 (20-75)
Male 41 (36%) 6 (40%)
Laboratory measurements
Tryptase (µg/L) [median, range] 22.9 (1.0-283) 4.85 (2.3-16.5)
Above 20 µg/L* 64 (56%)
MH (µmol/mol creatinine) 221 (44-2554) 68.5 (27-140)
[median, range]
Above 971/2th percentile 85 (74%) −
MIMA (mmol/mol creatinine) 2.3 (0.5-50.6) 1.4 (0.8-2.4)
[median, range]
Above 971/2th percentile 77 (67%) 1 (7%)
KIT mutation D816V*
Positive 36 (31%) −
Negative 50 (44%) −
Not assessed 29 (25%) 15 (100%)
Immunophenotype* 
Co-expression of CD117 
with CD2 and/or CD25
Positive 39 (34%) −
Negative 27 (23%) −
Not assessed 49 (43%) 15 (100%
* Minor WHO criterion12 MH: N– methylhistamine; MIMA: N– methylimidazole
acetic acid.
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ity and specificity of serum tryptase and urinary MH
and MIMA. All biochemical markers showed an area
under the curve (AUC) of >80% indicating excellent
test accuracy, with serum tryptase (AUC: 0.960; 95%
CI: [0.930 -0.991]) and urinary MIMA (AUC: 0.948;
95% CI: [0.911 - 0.985]) performing significantly better
(tryptase vs. MH p=0.0096, MIMA vs. MH p=0.0057)
than urinary MH (AUC: 0.881; 95% CI: [0.823-0.940]).
There was no significant difference between diagnostic
accuracy of tryptase and MIMA (p=0.5613). Analysis of
combinations of the three biochemical markers com-
pared with each marker alone showed no further
increase in diagnostic accuracy (data not shown).
Although it is not necessary to choose any particular
threshold for assessment of test accuracy of the various
biochemical markers, we selected various thresholds to
be used in patient care (Table 2). This means that a
patient with only cutaneous involvement and a serum
tryptase level below <20 mg/L (threshold used by the
WHO as minor criterion12) would have a 16% risk of
bone marrow involvement, and thus a diagnosis of
indolent systemic mastocytosis. This risk would fur-
ther decrease to 0% if such a patient had a tryptase
level <4.9 mg/L. In the absence of symptoms suggestive
of mastocytosis, and given present lack of a curative
therapy for systemic mastocytosis, this could be con-
sidered acceptable. On the other hand, this could help
convince patients and doctors to perform a bone mar-
row biopsy for those with cutaneous mastocytosis or
clinical symptoms suggestive of mastocytosis who
have elevated levels of serum tryptase and/or urinary
histamine metabolites. The probability that a patient
with a serum tryptase level of ≥21.9 mg/L had bone
marrow involvement was 98%, and with a level of
≥30.8 mg/L this rose even to 100%. Notably, serum
tryptase is not pathognomonic for mastocytosis.
Patients with high tryptase levels may harbor another
disease, such as a myeloid haematologic disorder.13
Remarkably, clinical symptoms were helpful in pre-
dicting bone marrow involvement. Obvioulsy, this
should be related to the referral pattern of this group of
patients to our university hospital. The majority of the
patients with anaphylactic reactions (14/24) and with
cutaneous mastocytosis (21/31 evaluable patients) had
systemic mastocytosis. In particular, patients with cuta-
neous mastocytosis with additional clinical symptoms
were almost all classified as systemic mastocytosis
(23/25). This agrees with the general assumption that
Figure 1. Distribution of patients according to bone marrow involvement. Distribution of subjects in indolent systemic mastocytosis/no
indolent systemic mastocytosis groups used for statistical analysis, according to bone marrow pathology and evaluation of WHO minor
criteria related to KIT mutation and CD2/CD25 immunophenotyping.
Patients (n=115) Controls (n=15)
Total group (n=130)
Mastocytosis (n=63)
(63 patients, 0 controls)
Patients Major Minor Minor Minor
(number) (BM) (BM) (CD2/CD25) (KIT)
56 + + +28/29 +27/40
(97%)* (68%)*
- 1/29 - 13/40
(3%)* (32%)*
2 + − + +
1 + − ND +
2 − + + +
2† − + + −
Patients Major Minor Minor Minor
(number) (BM) (BM) (CD2/CD25) (KIT)
48 − − +2/21 +2/28
(10%)* (7%)*
- 19/21 - 26/28
(90%)* (93%)*
2 − + − −
1 − + − ND
Bone marrow
not evaluable (n=16)
(14 patients, 2 controls)
- less than 2 cm marrow fields
- unreliable results with anti-CD117
- unreliable results with toluidine-blue
No mastocytosis (n=51)
(38 patients, 13 controls)
Major (BM): Multifocal dense infiltrates of mast cells (>15 mast cells aggregating) detected in sections of bone marrow
Minor (BM): >25% of mast cells are spindle-shaped in bone marrow sections
Minor (C-KIT): Detection of a c-kit point mutation at codon 816 in bone marrow or blood
Minor (CD2/CD25): Kit+mast cells in bone marrow or blood co-express CD2 or/and CD25
ND: not determined
*Number of patients with present (+) and absent (-) criterion/number of patients in which criterion is determined (percentage)
†Not included: according to WHO-criteria diagnosis systemic mastocytosis (tryptase >20 ng/mL)
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adult-onset cutaneous mastocytosis commonly repre-
sents systemic mastocytosis. By contrast, 4 out of the
15 patients with mediator-related symptoms only were
classified as such. The quality of the bone marrow
biopsy and additional immunohistochemistry is very
important, and we used strict criteria for final interpre-
tation. Mast cell infiltrates can be sparse, therefore
examination of sufficient marrow fields for a final neg-
ative diagnosis is required making additional immuno-
histochemistry essential. In our retrospective study, we
had to discard 12% of the biopsy specimens, the major-
ity due to small size. We used control patients instead
of healthy volunteers. Besides ethical issues, the main
reason for this selection was based upon the fact that
the clinical question was not to identify subjects with
or without bone marrow involvement in asymptomatic
volunteers, but patients who are considered to have
systemic mastocytosis. In conclusion, we have demon-
strated in a large representative cohort of patients that
blood and urinary analysis for tryptase and histamine
metabolites can help to predict those patients who
have bone marrow involvement representing indolent
systemic mastocytosis.
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Table 2. Sensitivity/specificity pairs and predictive values. Sensitivity/specificity pairs and positive predictive values (PPV) and negative
predictive values (NPV) of tryptase, MH and MIMA at various cut-off points. 
Marker Cut-off point Sensitivity Specificity PPV NPV
Tryptase ≥4.94 mg/L 100% 41.2% 67.0% 100%
≥21.9 mg/L 83.6% 98.0% 98.4% 83.3%
≥30.8 mg/L 67.2% 100% 100% 71.8%
MH ≥103 mmol/mol creatinine 100% 39.2% 66.3% 100%
≥171 mmol/mol creatinine 86.9% 70.6% 77.9% 81.8%
≥284 mmol/mol creatinine 55.7% 100% 100% 65.4%
MIMA ≥1.6 mmol/mol creatinine 100% 56.9% 73.5% 100%
≥2.0 mmol/mol creatinine 93.4% 82.4% 86.3% 91.3%
≥3.8 mmol/mol creatinine 49.2% 100% 100% 62.2%
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